A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2009
12/10/2009	US20090304819 Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance
12/10/2009	US20090304817 Glycosylation Variants of Ricin-Like Proteins
12/10/2009	US20090304805 Combinations and modes of administration of therapeutic agents and combination therapy
12/10/2009	US20090304803 Compositions and methods relating to target-specific photodynamic therapy
12/10/2009	US20090304771 Local Delivery System for the Chemotherapeutic Drug Paclitaxel
12/10/2009	US20090304735 Immunogenic Compositions
12/10/2009	US20090304728 Tem8 gene, expression forms and diagnostic and therapeutic uses thereof
12/10/2009	US20090304723 Mono-and disaccharide derivatives
12/10/2009	US20090304718 Antibody Molecules Specific for Fibroblast Activation Protein and Immunoconjugates Containing Them
12/10/2009	US20090304710 Novel anti-cd38 antibodies for the treatment of cancer
12/10/2009	US20090304709 Modulators of p-selectin glycoprotein ligand 1
12/10/2009	US20090304708 Preparation for the Prevention and/or Treatment of a Tissue Change of Mesenchymal Origin
12/10/2009	US20090304707 Monoclonal antibodies to basic fibroblast growth factor
12/10/2009	US20090304700 Conformation specific antibodies that bind trefoil factors
12/10/2009	US20090304695 Methods for treating cancer by inhibiting wnt signaling
12/10/2009	US20090304694 Ang2 and Vegf Inhibitor Combinations
12/10/2009	US20090304692 Triazine compounds as pi3 kinase and mtor inhibitors
12/10/2009	US20090304691 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
12/10/2009	US20090304690 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
12/10/2009	US20090304689 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
12/10/2009	US20090304688 Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators
12/10/2009	US20090304687 Methods of using cd40 binding agents
12/10/2009	US20090304674 Methods for treating disease by regulating cll cell survival
12/10/2009	US20090304666 Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
12/10/2009	US20090304663 Use of gsk-3 inhibitors for the treatment of prostate cancer
12/10/2009	US20090304662 Methods for Identifying and Targeting Tumor Stem Cells Based on Nuclear Morphology
12/10/2009	US20090304658 Method of proliferating lak cell
12/10/2009	US20090304651 Insulin-Like Growth Factor II (IGF-II) Binding Factors
12/10/2009	US20090304628 Stabilized pharmaceutical formulations that contain the interferons gamma and alpha in synergistic proportions
12/10/2009	US20090304597 Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies
12/10/2009	US20090304594 Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers
12/10/2009	US20090304592 Treatment of metastatic tumors
12/10/2009	US20090304584 Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
12/10/2009	US20090304583 Pathological tissue detection and treatment employing targeted benzoindole optical agents
12/10/2009	US20090304580 Anti-Pancreatic Cancer Antibodies
12/10/2009	US20090304579 Cancerous Disease Modifying Antibodies
12/10/2009	US20090304576 Device for delivery of anti-cancer agents to tissue
12/10/2009	DE102008027361A1 Composition, useful e.g. for the chemosensibilizing and simultaneous apoptosis induction of multidrug resistance of tumor cells and bacteria, comprises substituted disiloxane compound in combination with benzoxazole derivatives
12/10/2009	DE102008027331A1 Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase The use of indole-3-carboxylic acid esters to inhibit the microsomal prostaglandin E2 synthase
12/10/2009	CA2728243A1 Neuroinvasion inhibitor
12/10/2009	CA2727576A1 Inorganic nanoparticles, preparation and uses thereof
12/10/2009	CA2727018A1 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
12/10/2009	CA2727008A1 Use of a dead-box rna helicase for inducing cytokine production
12/10/2009	CA2726987A1 Stat3 inhibitors
12/10/2009	CA2726939A1 4,6-diphenylpyrid-2-ones against cancer
12/10/2009	CA2726917A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
12/10/2009	CA2726907A1 Dihydro-iso ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization
12/10/2009	CA2726885A1 Sirna of human osteopontin
12/10/2009	CA2726817A1 Identification and use of prognostic and predictive markers in cancer treatment
12/10/2009	CA2726673A1 Alpha helix mimetics and methods relating thereto
12/10/2009	CA2726644A1 Pharmaceutical combination
12/10/2009	CA2726603A1 Dosing regimen
12/10/2009	CA2726579A1 Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
12/10/2009	CA2726537A1 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
12/10/2009	CA2726472A1 Solid pharmaceutical formulations comprising bibw 2992
12/10/2009	CA2726358A1 Inhibitors of akt activity
12/10/2009	CA2726317A1 Inhibitors of akt activity
12/10/2009	CA2726258A1 Anti-tumoural effects of cannabinoid combinations
12/10/2009	CA2726257A1 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)
12/10/2009	CA2725749A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
12/10/2009	CA2723918A1 Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
12/09/2009	EP2131198A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
12/09/2009	EP2130920A2 Beta-like glycoprotein hormone polypeptide and heterodimer
12/09/2009	EP2130919A1 IL-21 antagonists
12/09/2009	EP2130834A1 Novel sulfonated sugar derivative, and use thereof for medicinal agent
12/09/2009	EP2130832A1 Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation
12/09/2009	EP2130831A1 CDC25 inhibitors
12/09/2009	EP2130829A1 Novel hydroxyindole derivative
12/09/2009	EP2130826A1 Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
12/09/2009	EP2130822A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
12/09/2009	EP2130552A1 Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
12/09/2009	EP2130550A1 Use of a dead-box RNA helicase to induce the production of cytokines
12/09/2009	EP2130548A2 Growth Hormone Releasing Peptides
12/09/2009	EP2130544A2 Processes for obtaining lignan extracts and compositions containing the lignan extracts
12/09/2009	EP2130537A1 N3 alkylated benzimidazole derivatives as mek inhibitors
12/09/2009	EP2130536A1 N3 alkylated benzimidazole derivatives as mek inhibitors
12/09/2009	EP2129668A1 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
12/09/2009	EP2129666A2 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
12/09/2009	EP2129662A2 C21-deoxy ansamycin derivatives as antitumor agents
12/09/2009	EP2129402A2 Receptor and antigen targeted prodrug
12/09/2009	EP2129397A2 Methods and compositions for treating tumor diseases
12/09/2009	EP2129396A2 Antibodies against erbb3 and uses thereof
12/09/2009	EP2129379A1 Imidazoquinolines as dual lipid kinase and mtor inhibitors
12/09/2009	EP1981843B1 Vitamin d analog: nel, methods and uses thereof
12/09/2009	EP1940848B1 Antimitotic rhizoxin derivatives of burkholderia rhizoxina, method for producing said derivatives and use thereof
12/09/2009	EP1871765B1 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
12/09/2009	EP1694707B1 Human anti-idiotypic antibody fragments that mimic her-2/neu
12/09/2009	EP1692140B1 Compositions useful as inhibitors of protein kinases
12/09/2009	EP1679370B1 Method of evaluating cancerization degree
12/09/2009	EP1554256B1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
12/09/2009	EP1518517B1 Drug-delivery endovascular stent
12/09/2009	EP1458754B1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/09/2009	EP1443933B1 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
12/09/2009	EP1404368B1 Mutant forms of cholera holotoxin as an adjuvant
12/09/2009	EP1392642B1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
12/09/2009	EP1252144B1 Substituted glutarimides and use thereof il-12 production inhibitors
12/09/2009	EP1129110B1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
12/09/2009	EP1040198B1 Recombinant rhabdovirus containing a heterologous fusion protein
12/09/2009	CN101600720A Phosphoinositide 3-kinase inhibitor compounds and methods of use
12/09/2009	CN101600718A Imidazo[1,2-B]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives and their use as protein kinase inhibitors

1 ... 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 ... 2211